Company profile: VistaGen Therapeutics
1.1 - Company Overview
Company description
- Provider of investigational biopharmaceutical therapies for CNS diseases and disorders: Fasedienol (for multiple anxiety disorders), Itruvone (for major depressive disorder and other depression-related conditions), PH80 (menopausal hot flashes, premenstrual dysphoric disorder, migraines), PH15 (to improve cognition), PH284 (appetite-related disorders, including Cachexia), AV-101 (oral prodrug targeting the NMDA receptor glycine site).
Products and services
- AV-101: Oral prodrug antagonizing the NMDA receptor glycine site, aimed at treating multiple CNS diseases and disorders through glycine-site antagonism
- Fasedienol: Rapid-onset nasal spray for multiple anxiety disorders, designed to enable fast relief without the side effects of current anti-anxiety products
- Itruvone: Investigational nasal spray aimed at treating major depressive disorder and other depression-related neuropsychiatric conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to VistaGen Therapeutics
Aspen Neuroscience
HQ: United States
Website
- Description: Provider of personalized, autologous iPSC-derived neuron replacement therapies for Parkinson’s disease. Pipeline includes ANPD001, a personalized cell therapy for sporadic Parkinson’s disease in IND-enabling studies, and ANPD002, a gene-corrected autologous neuron therapy targeting genetic variants, focusing on the GBA gene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspen Neuroscience company profile →
Rapid Dose Therapeutics
HQ: Canada
Website
- Description: Provider of pharma-tech oral fast-dissolving drug delivery solutions, including QuickStrip for direct bloodstream delivery of pharmaceuticals and over-the-counter medicines; RDMx + QuickStrip for enabling delivery of large therapeutic molecules; Rapid Energy, Vitamin B12, and Melatonin QuickStrip products; and versions for elderly and pediatric patients needing simplified, rapid dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapid Dose Therapeutics company profile →
BioQ Pharma
HQ: United States
Website
- Description: Provider of pre-filled, ready-to-use infusion delivery systems and medicines. Offerings include invenious, a platform for infusible medicines to simplify infusion and enhance safety and sterility; Ropivacaine Readyfusor, a pre-filled infusion for surgical procedures as a safer, more efficient alternative to fillable pain pumps; and invenious/propofol, a ready-to-use infusion with programmable flow and bolus for procedural anesthesia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioQ Pharma company profile →
Iama Therapeutics
HQ: Italy
Website
- Description: Provider of novel neuroscience therapeutics for pediatric brain disorders, advancing drug discovery to address unmet needs; lead candidate IAMA-6 is an orally administered small molecule targeting NKCC1-associated neuronal hyperexcitability, currently in Phase 1 clinical trials for autism and epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iama Therapeutics company profile →
Rodin Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics for neurological disorders by applying insights of epigenetics, leveraging key epigenetic modulators of CNS function and privileged access to Proteros’ best-in-class structural biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rodin Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for VistaGen Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to VistaGen Therapeutics
2.2 - Growth funds investing in similar companies to VistaGen Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for VistaGen Therapeutics
4.2 - Public trading comparable groups for VistaGen Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →